Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

CHEK2 1100delC Variant and Breast Cancer Risk in Caucasians: A Meta-analysis Based on 25 Studies with 29,154 Cases and 37,064 Controls

  • Yang, Yuan (Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University) ;
  • Zhang, Fan (School of Public Health and Health Management, Chongqing Medical University) ;
  • Wang, Yang (School of Public Health and Health Management, Chongqing Medical University) ;
  • Liu, Sheng-Chun (Department of Endocrine and Breast Surgery, the First Affiliated Hospital, Chongqing Medical University)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Links between the CHEK2 1100delC heterozygote and breast cancer risk have been extensively explored. However, both positive and negative associations with this variant have been reported in individual studies. For a detailed assessment of the CHEK2 1100delC heterozygote and breast cancer risk, relevant studies published as recently as May 2012 were identified using PUBMED and EMBASE and selected using a priori defined criteria. The strength of the relationship between the CHEK2 1100delC variant and breast cancer risks was assessed by odds ratios (ORs) under the fixed effects model. A total of 29,154 cases and 37,064 controls from 25 case-control studies were identified in this meta-analysis. The CHEK2 1100delC heterozygote was more frequently detected in cases than in controls (1.34% versus 0.44%). A significant association was found between CHEK2 1100delC heterozygote and breast cancer risk (OR=2.75, 95% CI: [2.25, 3.36]). The ORs and CIs were 2.33 (95% CI: [1.79, 3.05]), 3.72 (95% CI: [2.61, 5.31]) and 2.78 (95% CI: [2.28, 3.39]) respectively in unselected, family, early-onset breast cancer subgroups. The CHEK2 1100delC variant could be a potential factor for increased breast cancer risk in Caucasians. However, more consideration is needed in order to apply it to allele screening or other clinical work.

Keywords

References

  1. Baeyens A, Claes K, Willems P, et al (2005). Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation. Cancer Genet Cytogenet, 163, 106-12. https://doi.org/10.1016/j.cancergencyto.2005.04.017
  2. Baig RM, Mahjabeen I, Sabir M, et al (2011). Genetic changes in the PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev, 12, 2773-8.
  3. Bell DW, Kim SH, Godwin AK, et al (2007). Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer, 121, 2661-7. https://doi.org/10.1002/ijc.23026
  4. Bell DW, Varley JM, Szydlo TE, et al (1999). Heterozygous germ line hCHEK2 mutations in Li-Fraumeni syndrome. Science, 286, 2528-31. https://doi.org/10.1126/science.286.5449.2528
  5. Bernstein JL, Teraoka SN, John EM, et al (2006). The $CHEK2^\ast1100delC$ allelic variant and risk of breast cancer: Screening results from the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev, 15, 348-52. https://doi.org/10.1158/1055-9965.EPI-05-0557
  6. CHEK2 Breast Cancer Consortium (2004). $CHEK2^\ast1100delC$ and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer patient cases and 9,065 controls from 10 studies. Am J Hum Genet, 74, 1175-82. https://doi.org/10.1086/421251
  7. Chen S, Parmigiani G (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol, 25, 1329-33. https://doi.org/10.1200/JCO.2006.09.1066
  8. Choi DH, Cho DY, Lee MH, et al (2008). The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat, 112, 569-73. https://doi.org/10.1007/s10549-007-9878-z
  9. Cybulski C, Wokołorczyk D, Huzarski T, et al (2007). A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat, 102, 119-22. https://doi.org/10.1007/s10549-006-9320-y
  10. Dufault MR, Betz B, Wappenschmidt B, et al (2004). Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer, 110, 320-5. https://doi.org/10.1002/ijc.20073
  11. Einarsdottir K, Humphreys K, Bonnard C, et al (2006). Linkage disequilibrium mapping of CHEK2: Common variation and breast cancer risk. PLoS Med, 3, e168. https://doi.org/10.1371/journal.pmed.0030168
  12. Fletcher O, Johnson N, Dos Santos Silva I, et al (2009). Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of $CHEK2^\ast1100delC$ in 1,828 Bilateral Breast Cancers and 7,030 Controls. Cancer Epidemiol Biomarkers Prev, 18, 230-4. https://doi.org/10.1158/1055-9965.EPI-08-0416
  13. Friedrichsen DM, Malone KE, Doody DR, et al (2004). Frequency of CHEK2 mutations in a population based, patient case-control study of breast cancer in young women. Breast Cancer Res, 6, R629-35. https://doi.org/10.1186/bcr933
  14. Iniesta MD, Gorin MA, Chien LC, et al (2010). Absence of $CHEK2^\ast1100delC$ mutation in families with hereditary breast cancer in North America. Cancer Genet Cytogenet, 202, 136-40. https://doi.org/10.1016/j.cancergencyto.2010.07.124
  15. Kleibl Z, Novotny J, Bezdickova D, et al (2005). The CHEK2 c. 1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat, 90, 165-7. https://doi.org/10.1007/s10549-004-4023-8
  16. Lee AS, Ang P (2008). $CHEK2^\ast1100delC$ screening of Asian women with a family history of breast cancer is unwarranted. J Clin Oncol, 26, 2419 (author reply 2419-20).
  17. Mateus Pereira LH, Sigurdson AJ, Doody MM, et al (2004). CHEK2:1100delC and female breast cancer in the United States. Int J Cancer, 112, 541-3. https://doi.org/10.1002/ijc.20439
  18. McInerney NM, Miller N, Rowan A, et al (2010). Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat, 121, 203-10. https://doi.org/10.1007/s10549-009-0540-9
  19. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al (2002). Low-penetrance susceptibility to breast cancer due to $CHEK2(^\ast)1100delC$ in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31, 55-9. https://doi.org/10.1038/ng879
  20. Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71. https://doi.org/10.1126/science.7545954
  21. Offit K, Pierce H, Kirchhoff T, et al (2003). Frequency of $CHEK2^\ast1100delC$ in New York breast cancer cases and controls. BMC Med Genet, 4, 1.
  22. Overton, Randall C (1998). A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects. Psychological Methods, 3, 354-79. https://doi.org/10.1037/1082-989X.3.3.354
  23. Rajkumar T, Soumittra N, Nancy NK, et al (2003). BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev, 4, 203-8.
  24. Rashid MU, Jakubowska A, Justenhoven C, et al (2005). German populations with infrequent $CHEK2^\ast1100delC$ and minor associations with early-onset and familial breast cancer. Eur J Cancer, 41, 2896-903. https://doi.org/10.1016/j.ejca.2005.04.049
  25. Shih HA, Couch FJ, Nathanson KL, et al (2002). BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol, 20, 994-9. https://doi.org/10.1200/JCO.20.4.994
  26. Sodha N, Bullock S, Taylor R, et al (2002). CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer, 87, 1445-8. https://doi.org/10.1038/sj.bjc.6600637
  27. Song CG, Hu Z, Yuan WT, et al (2006). CHEK2 c. 1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 23, 443-5. (In Chinese)
  28. Thirthagiri E, Cheong LS, Yip CH, et al (2009). $CHEK2^\ast1100delC$ does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia. Fam Cancer, 8, 355-8. https://doi.org/10.1007/s10689-009-9244-x
  29. Vahteristo P, Bartkova J, Eerola H, et al (2002). A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet, 71, 432-8. https://doi.org/10.1086/341943
  30. Weischer M, Bojesen SE, Ellervik C, et al (2008). $CHEK2^\ast1100delC$ Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls. J Clin Oncol, 26, 542-8. https://doi.org/10.1200/JCO.2007.12.5922
  31. Weischer M, Bojesen SE, Tybjaerg-Hansen A, et al (2007). Increased risk of breast cancer associated with $CHEK2^\ast1100delC$. J Clin Oncol, 25, 57-63.
  32. Wooster R, Bignell G, Lancaster J, et al (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-92. https://doi.org/10.1038/378789a0
  33. World Cancer Report (2008). International Agency for Research on Cancer. Available at: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.
  34. Zhang B, Beeghly-Fadiel A, Long J, and Zheng W (2011). Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol, 12, 477-88. https://doi.org/10.1016/S1470-2045(11)70076-6
  35. Zhang S, Phelan CM, Zhang P, et al (2008). Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study. Cancer Res, 68, 2154-7. https://doi.org/10.1158/0008-5472.CAN-07-5187

Cited by

  1. Lack of an Association between Passive Smoking and Incidence of Female Breast Cancer in Non-Smokers: Evidence from 10 Prospective Cohort Studies vol.8, pp.10, 2013, https://doi.org/10.1371/journal.pone.0077029
  2. Prospective study of high-risk, BRCA1/2-mutation negative women: the ‘negative study’ vol.14, pp.1, 2014, https://doi.org/10.1186/1471-2407-14-221
  3. Frequency of CHEK2 gene mutations in breast cancer patients from Republic of Bashkortostan vol.48, pp.1, 2014, https://doi.org/10.1134/S0026893314010026
  4. Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5211
  5. *1100delC Heterozygotes Estimated From the Copenhagen General Population Study vol.34, pp.11, 2016, https://doi.org/10.1200/JCO.2015.63.3594
  6. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel vol.161, pp.1, 2017, https://doi.org/10.1007/s10549-016-4038-y
  7. Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis vol.22, pp.4, 2018, https://doi.org/10.1007/s40291-018-0344-x